Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20384956rdf:typepubmed:Citationlld:pubmed
pubmed-article:20384956lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:20384956lifeskim:mentionsumls-concept:C0002878lld:lifeskim
pubmed-article:20384956lifeskim:mentionsumls-concept:C1280551lld:lifeskim
pubmed-article:20384956lifeskim:mentionsumls-concept:C0019134lld:lifeskim
pubmed-article:20384956lifeskim:mentionsumls-concept:C0456081lld:lifeskim
pubmed-article:20384956pubmed:issue3lld:pubmed
pubmed-article:20384956pubmed:dateCreated2010-6-22lld:pubmed
pubmed-article:20384956pubmed:abstractTextA major cause of death in dogs with immune-mediated hemolytic anemia (IMHA) is thromboembolism. Previous studies suggest unfractionated heparin (UH) is not effective in preventing thromboembolism in IMHA; however, subtherapeutic dosing could explain the seeming lack of efficacy.lld:pubmed
pubmed-article:20384956pubmed:languageenglld:pubmed
pubmed-article:20384956pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20384956pubmed:citationSubsetIMlld:pubmed
pubmed-article:20384956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20384956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20384956pubmed:statusMEDLINElld:pubmed
pubmed-article:20384956pubmed:issn0891-6640lld:pubmed
pubmed-article:20384956pubmed:authorpubmed-author:SmithS ASAlld:pubmed
pubmed-article:20384956pubmed:authorpubmed-author:ArmstrongP...lld:pubmed
pubmed-article:20384956pubmed:authorpubmed-author:FinkeMMlld:pubmed
pubmed-article:20384956pubmed:authorpubmed-author:PolzinD JDJlld:pubmed
pubmed-article:20384956pubmed:authorpubmed-author:HelmondS ESElld:pubmed
pubmed-article:20384956pubmed:issnTypePrintlld:pubmed
pubmed-article:20384956pubmed:volume24lld:pubmed
pubmed-article:20384956pubmed:ownerNLMlld:pubmed
pubmed-article:20384956pubmed:authorsCompleteYlld:pubmed
pubmed-article:20384956pubmed:pagination597-605lld:pubmed
pubmed-article:20384956pubmed:meshHeadingpubmed-meshheading:20384956...lld:pubmed
pubmed-article:20384956pubmed:meshHeadingpubmed-meshheading:20384956...lld:pubmed
pubmed-article:20384956pubmed:meshHeadingpubmed-meshheading:20384956...lld:pubmed
pubmed-article:20384956pubmed:meshHeadingpubmed-meshheading:20384956...lld:pubmed
pubmed-article:20384956pubmed:meshHeadingpubmed-meshheading:20384956...lld:pubmed
pubmed-article:20384956pubmed:meshHeadingpubmed-meshheading:20384956...lld:pubmed
pubmed-article:20384956pubmed:meshHeadingpubmed-meshheading:20384956...lld:pubmed
pubmed-article:20384956pubmed:meshHeadingpubmed-meshheading:20384956...lld:pubmed
pubmed-article:20384956pubmed:meshHeadingpubmed-meshheading:20384956...lld:pubmed
pubmed-article:20384956pubmed:meshHeadingpubmed-meshheading:20384956...lld:pubmed
pubmed-article:20384956pubmed:meshHeadingpubmed-meshheading:20384956...lld:pubmed
pubmed-article:20384956pubmed:articleTitleTreatment of immune-mediated hemolytic anemia with individually adjusted heparin dosing in dogs.lld:pubmed
pubmed-article:20384956pubmed:affiliationSection of Small Animal Internal Medicine, Veterinary Clinical Sciences Department, College of Veterinary Medicine, University of Minnesota, Saint Paul, MN, USA.lld:pubmed
pubmed-article:20384956pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20384956pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:20384956pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed